Reading this on a mobile device? Try our optimized mobile version here:

November 1, 2012
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • Report: Biotech industry raised $1.2B in Q3 venture funding
    Venture capital investments in the biotechnology sector jumped by 64% to $1.2 billion while the number of biotech-related deals increased by 22% to 116 during the third quarter of 2012, according to the quarterly MoneyTree Report. Overall venture funding in the life sciences industry, however, dropped 19% in dollars and 12% in terms of the number of deals during the first three quarters of 2012 compared with the same period last year. Patent Docs blog (10/30) LinkedInFacebookTwitterEmail this Story
Meetings, Earning, Markets Canceled Ahead of 'Frankenstorm'
Pfizer Inc. and Vertex Pharmaceuticals Inc. each postponed earnings reports due to disruptions in transit and other preparations for Hurricane Sandy, a tropical storm of unprecedented size and strength complicated by a number of other meteorological events. Find out the details.

  Health Care & Policy 
  • Millennium-Seattle's lymphoma drug gets conditional EU approval
    Millennium: The Takeda Oncology Company and Seattle Genetics obtained conditional approval from the European Commission to market Adcetris, or brentuximab vedotin, for adults with relapsed or refractory systemic anaplastic large cell lymphoma, as well as relapsed or refractory CD30-positive Hodgkin lymphoma who have received autologous stem cell transplants or at least two therapies when transplant or chemotherapy aren't appropriate. Seattle will receive $25 million for each approval. Genetic Engineering & Biotechnology News (10/31) LinkedInFacebookTwitterEmail this Story
  • Biogen's hemophilia drug achieves goal in Phase III study
    Biogen Idec said its investigational hemophilia A drug controlled 98% of bleeding episodes with only one or two injections a week during a late-stage trial compared with an average of three to four treatments with existing treatments. The company plans to submit the drug for FDA approval before July and to file an application in Europe after a pediatric trial is completed. Reuters (10/31) LinkedInFacebookTwitterEmail this Story
  • Pediatricians express support for embryonic stem cell research
    The American Academy of Pediatrics has published a policy statement in the journal Pediatrics expressing support for embryonic stem cell research. "It is anticipated that continued advances will have a substantial impact on the understanding and treatment of pediatric diseases," the group said. In consideration of the debate surrounding the use of the cells, the group said any policy regarding this should note the differing opinions. As an alternative to ESCs, induced pluripotent stem cells show "great promise," the group added. MedPage Today (free registration) (10/30) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  • Conn. startup raises $6.6M in funding round
    New Haven Pharmaceuticals secured $6.6 million in a Series A financing round from private and public investors. NHP utilizes technology licensed from Yale University to develop proprietary prescription pharmaceuticals using existing drugs or active pharmaceutical ingredients that are generally known to be safe. The startup plans to apply for FDA approval next year for a slow-release aspirin product for secondary prevention of stroke and acute cardiovascular events. Mass High Tech (Boston) (10/29) LinkedInFacebookTwitterEmail this Story
First class, non-stop, global connections.
BIO conferences provide strategic access for the biotech community to accelerate business relationships. We catalyze partnerships through our global portfolio of events, including the world's largest biotech gathering, the BIO International Convention. Learn more about BIO events.
  Industry Deals 
  Food & Agriculture 
  • BIO, ASTA closer to framework for seed patent expiration
    BIO and the American Seed Trade Association have completed the initial phase of an agreement aimed at creating guidelines on how to handle patent expirations involving biotech seed technology. The accord, once implemented, will support regulatory approvals of biotech seeds in other countries. The Generic Event Marketability and Access Agreement "is an important first step, but the industry must continue moving forward on the second half of the accord, which will ensure seed companies are able to stack with generic traits to create innovative products for farmers," said Paul Schickler, president of DuPont's Pioneer agricultural division. Reuters (10/31) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • Novozymes to buy 10% stake in Beta Renewables for $116M
    Novozymes has agreed to pay about $116 million to acquire a 10% interest in Beta Renewables, which is part of Italy-based Gruppo Mossi and Ghisolfi. Under the deal, Novozymes will become the preferred enzyme provider for Beta Renewables' cellulosic-ethanol facilities. "Novozymes expects Beta Renewables to be able to contract 15-25 new cellulosic biofuel facilities in the next three to five years," the Danish company said. Reuters (10/29) LinkedInFacebookTwitterEmail this Story

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or 

  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

Nature does not equally distribute energy. Some people are born old and tired while others are going strong at 70."
--Dorothy Thompson,
American journalist and radio broadcaster

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information